200 related articles for article (PubMed ID: 38767705)
1. PAQR4 oncogene: a novel target for cancer therapy.
Patil D; Raut S; Joshi M; Bhatt P; Bhatt LK
Med Oncol; 2024 May; 41(6):161. PubMed ID: 38767705
[TBL] [Abstract][Full Text] [Related]
2. PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway.
Zhao G; Shi X; Sun Z; Zhao P; Lu Z
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1602-1613. PubMed ID: 34718369
[TBL] [Abstract][Full Text] [Related]
3. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
[No Abstract] [Full Text] [Related]
4. SPAG5: An Emerging Oncogene.
He J; Green AR; Li Y; Chan SYT; Liu DX
Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-370 inhibits the proliferation, invasion and EMT of gastric cancer cells by directly targeting PAQR4.
Feng Y; Sun T; Yu Y; Gao Y; Wang X; Chen Z
J Pharmacol Sci; 2018 Oct; 138(2):96-106. PubMed ID: 30322804
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis of the prognostic and immunological role of PAQR4.
Wang K; Meng J; Wang X; Yan M; Liu S; Yang S; Xu S; Liu D; Li C; Yang K
Sci Rep; 2022 Dec; 12(1):21268. PubMed ID: 36481756
[TBL] [Abstract][Full Text] [Related]
7. Pancancer Analysis of the Prognostic and Immunotherapeutic Value of Progestin and AdipoQ Receptor 4.
Yang Z; Zhu Y; Li Z; Pu Z; Lin Y; Deng Y; Li N; Peng F
Comput Math Methods Med; 2022; 2022():2528164. PubMed ID: 36573110
[TBL] [Abstract][Full Text] [Related]
8. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
9. PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation.
Zhang H; Han R; Ling ZQ; Zhang F; Hou Y; You X; Huang M; Zhao Z; Wang Z; Chen Y
Carcinogenesis; 2018 Mar; 39(3):439-446. PubMed ID: 29228296
[TBL] [Abstract][Full Text] [Related]
10. The pharmacogenomics of drug resistance to protein kinase inhibitors.
Gillis NK; McLeod HL
Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
[TBL] [Abstract][Full Text] [Related]
11. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
12. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
[TBL] [Abstract][Full Text] [Related]
13. Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway.
Ye J; Gao M; Guo X; Zhang H; Jiang F
Biomed Pharmacother; 2020 Jul; 127():110223. PubMed ID: 32413672
[TBL] [Abstract][Full Text] [Related]
14. Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer.
Pedersen L; Panahandeh P; Siraji MI; Knappskog S; Lønning PE; Gordillo R; Scherer PE; Molven A; Teigen K; Halberg N
Cancer Res; 2020 Jun; 80(11):2163-2174. PubMed ID: 32291319
[TBL] [Abstract][Full Text] [Related]
15. High PAQR4 mRNA Expression May Play a Key Role in Prognosis of Kidney Renal Papillary Cell Carcinoma.
Liu C; Cai W; Tang P; Li C
Ann Clin Lab Sci; 2023 Sep; 53(5):701-711. PubMed ID: 37945022
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.
Qu C; Ma T; Yan X; Li X; Li Y
Math Biosci Eng; 2022 Jan; 19(3):3069-3090. PubMed ID: 35240821
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs and cancer resistance: A new molecular plot.
Fanini F; Fabbri M
Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
[TBL] [Abstract][Full Text] [Related]
18. Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role.
Kannampuzha S; Gopalakrishnan AV
Med Oncol; 2023 Aug; 40(9):264. PubMed ID: 37550533
[TBL] [Abstract][Full Text] [Related]
19. LINC00162 regulates cell proliferation and apoptosis by sponging PAQR4-targeting miR-485-5p.
Lee WJ; Ji H; Jeong SD; Pandey PR; Gorospe M; Kim HH
J Cell Physiol; 2022 Jul; 237(7):2943-2960. PubMed ID: 35491694
[TBL] [Abstract][Full Text] [Related]
20. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
